Use of nefiracetam for treating neurodegeneration

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4015 (2006.01) A61P 25/28 (2006.01) C07D 207/27 (2006.01)

Patent

CA 2457982

N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as in an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Activities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

On utilise N-(2,6-diméthylphényl)-2-(2-oxo-1-pyrrolidinyl)acétamide, ainsi que ses sels, dans la préparation de médicaments, en particulier de compositions pharmaceutiques dont il constitue le principe actif, pour le traitement de la neurodégénérescence, notamment chez les patients humains ayant subi un accident vasculaire cérébral. L'administration rapide, après l'accident vasculaire cérébral, de la nefiracétame ou de son sel dans lesdites compositions pharmaceutiques favorise l'amélioration des activités quotidiennes et la récupération, au moins partielle, des patients.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of nefiracetam for treating neurodegeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of nefiracetam for treating neurodegeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nefiracetam for treating neurodegeneration will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1896601

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.